Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1
暂无分享,去创建一个
William C. Olson | Elizabeth Michael | N. Schülke | John P. Moore | K. Barnes | R. Sanders | S. Beddows | M. Kirschner | M. Franti | E. Michael | Thomas A. Ketas | Paul J Maddon | W. Olson | Rogier W. Sanders | Kelly Barnes | Simon Beddows | Norbert Schülke | Marc Kirschner | Michael Franti | Thomas Ketas | Paul J. Maddon | P. Maddon | Kelly Barnes
[1] Brian Seed,et al. Codon usage limitation in the expression of HIV-1 envelope glycoprotein , 1996, Current Biology.
[2] S. A. Gallo,et al. The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.
[3] D. Montefiori,et al. Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization , 2002, Journal of Virology.
[4] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[5] R. Compans,et al. Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. , 2004, Virology.
[6] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[7] J. Bradac,et al. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.
[8] R. Desrosiers,et al. Viral persistence: HIV's strategies of immune system evasion. , 2002, Annual review of medicine.
[9] J. Moore,et al. Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion , 2003, Journal of Virology.
[10] B. Korber,et al. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.
[11] A. McMichael,et al. DNA vaccines against human immunodeficiency virus type 1 , 2004, Immunological reviews.
[12] E. Hunter,et al. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation , 1995, Journal of virology.
[13] Bette T. Korber,et al. Immune control of HIV: the obstacles of HLA and viral diversity , 2001, Nature Immunology.
[14] J. Haas,et al. Identification of Two Sequences in the Cytoplasmic Tail of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein That Inhibit Cell Surface Expression , 2001, Journal of Virology.
[15] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[16] I. Mathiesen. Electropermeabilization of skeletal muscle enhances gene transfer in vivo , 1999, Gene Therapy.
[17] John P. Moore,et al. Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.
[18] S. Harrison,et al. A Chimeric Protein of Simian Immunodeficiency Virus Envelope Glycoprotein gp140 and Escherichia coli Aspartate Transcarbamoylase , 2004, Journal of Virology.
[19] B. Graham. Clinical trials of HIV vaccines. , 2002, Annual review of medicine.
[20] J. Bonifacino,et al. A Membrane-proximal Tyrosine-based Signal Mediates Internalization of the HIV-1 Envelope Glycoprotein via Interaction with the AP-2 Clathrin Adaptor* , 1998, The Journal of Biological Chemistry.
[21] D R Burton,et al. gp120: Biologic aspects of structural features. , 2001, Annual review of immunology.
[22] J. Sodroski,et al. Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. , 2003, AIDS research and human retroviruses.
[23] S. Zolla-Pazner,et al. The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.
[24] J. Ulmer,et al. Increased DNA Vaccine Delivery and Immunogenicity by Electroporation In Vivo , 2000, The Journal of Immunology.
[25] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[26] Q. Sattentau,et al. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.
[27] J. Sodroski,et al. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.
[28] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[29] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[30] Gary J. Nabel,et al. The need for a global HIV vaccine enterprise. Policy forum. , 2003 .
[31] L. Stamatatos,et al. Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus , 2002, Journal of Virology.
[32] A. McMichael,et al. Prospects for an AIDS vaccine. , 2003, Clinical medicine.
[33] J. Moore,et al. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.
[34] Richard D. Leapman,et al. Oligomeric Structure of the Human Immunodeficiency Virus Type 1 Envelope Protein on the Virion Surface , 2002, Journal of Virology.
[35] Q. Sattentau,et al. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. , 2004, Vaccine.
[36] Min Lu,et al. Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein , 2002, Journal of Virology.
[37] D. Weiner,et al. DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade , 2004, Clinical Microbiology Reviews.
[38] A. Trkola,et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.
[39] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[40] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[41] J. Sodroski,et al. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. , 2004, Virology.
[42] Q. Sattentau,et al. Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design". , 1997, Immunology letters.
[43] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[44] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[45] J. Bonifacino,et al. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. , 1997, Virology.
[46] J. Binley,et al. Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2002, Journal of Virology.
[47] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[48] S. Zolla-Pazner,et al. Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.
[49] J. Sodroski,et al. Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers , 2001, Journal of Virology.
[50] Guillaume Blot,et al. The Highly Conserved C-Terminal Dileucine Motif in the Cytosolic Domain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Is Critical for Its Association with the AP-1 Clathrin Adapter , 2001, Journal of Virology.
[51] John P. Moore,et al. Urgently needed: a filter for the HIV-1 vaccine pipeline , 2004, Nature Medicine.
[52] D. Burton,et al. gp41: HIV's shy protein , 2004, Nature Medicine.
[53] Q. Sattentau,et al. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. , 1997, Immunology letters.
[54] A. Trkola,et al. Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[55] John P. Moore,et al. Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.
[56] J. Mascola,et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.
[57] A. Trkola,et al. Enhancement of Human Immunodeficiency Virus Type 1 Infection by the CC-Chemokine RANTES Is Independent of the Mechanism of Virus-Cell Fusion , 1999, Journal of Virology.
[58] J. Mascola,et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160 , 1997, Journal of virology.
[59] J. Binley,et al. Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions , 2003, Journal of Virology.
[60] J. Mascola,et al. The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region , 2001, Journal of Virology.
[61] Yiming Shao,et al. Enhanced: The Need for a Global HIV Vaccine Enterprise , 2003, Science.
[62] Jon Cohen,et al. Public health. AIDS vaccine trial produces disappointment and confusion. , 2003, Science.
[63] C. Barbas,et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.
[64] M. Feinberg,et al. Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.
[65] J. Sodroski,et al. Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin , 2002, Journal of Virology.
[66] A. McMichael,et al. HIV vaccines 1983–2003 , 2003, Nature Medicine.
[67] B. Moss,et al. Promoting Trimerization of Soluble Human Immunodeficiency Virus Type 1 (HIV-1) Env through the Use of HIV-1/Simian Immunodeficiency Virus Chimeras , 2004, Journal of Virology.
[68] E. Freed,et al. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[69] J. Moore,et al. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. , 1994, Journal of acquired immune deficiency syndromes.
[70] New hope for AIDS vaccine. , 2003, Lancet.
[71] John P. Moore,et al. Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development , 2001, Journal of Virology.
[72] P. Doherty,et al. Limited Breadth of a T-Helper Cell Response to a Human Immunodeficiency Virus Envelope Protein , 2003, Journal of Virology.
[73] L. Stamatatos,et al. Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.
[74] J. Binley,et al. A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.
[75] J. Sodroski,et al. Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.
[76] D. Ho,et al. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection , 1996, Journal of virology.
[77] D. Burton,et al. Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.
[78] D. Scherman,et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[79] J. Sodroski,et al. Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d , 2004, Journal of Virology.
[80] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[81] R. Compans,et al. Surface Stability and Immunogenicity of the Human Immunodeficiency Virus Envelope Glycoprotein: Role of the Cytoplasmic Domain , 2004, Journal of Virology.
[82] P. Doherty,et al. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing , 2001, Proceedings of the National Academy of Sciences of the United States of America.